We are live on ! Find out more
CAC

Cowen and Company Portfolio holdings

AUM $2.97B
1-Year Est. Return 105.26%
This Fund
S&P 500
This Quarter Est. Return
+10.51%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.05%
5 Year Est. Return
+670.56%
10 Year Est. Return
–
AUM
$1.21B
AUM Growth
+$355M
Cap. Flow
+$316M
Cap. Flow %
26.21%
Top 10 Hldgs %
40.06%
Holding
747
New
182
Increased
169
Reduced
181
Closed
163

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$64M
2
MMP
Magellan Midstream Partners, L.P.
MMP
+$42.3M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$41.5M
4
PTCT icon
PTC Therapeutics
PTCT
+$39.1M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$31.8M

Top Sells

Rank Stock Value
1
SLVM icon
Sylvamo
SLVM
+$99.5M
2
KVSC
Khosla Ventures Acquisition Co. III Class A Common Stock
KVSC
+$24.5M
3
TIOA
Tio Tech A Class A Ordinary Share
TIOA
+$22.2M
4
IMVT icon
Immunovant
IMVT
+$19.4M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 36.03%
2 Financials 28.77%
3 Technology 9.99%
4 Energy 5.75%
5 Consumer Discretionary 4.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGB.WS
376
DELISTED
Apollo Strategic Growth Capital II Warrants, each exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share
APGB.WS
$12.5K ﹤0.01%
102,200
+76,200
+293% +$9.83K
AIRJW
377
AirJoule Technologies Warrant
AIRJW
$84.5M
$12.3K ﹤0.01%
176,716
-23,284
-12% -$1.7K
BRD.WS
378
DELISTED
Beard Energy Transition Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
BRD.WS
$12.3K ﹤0.01%
175,777
+90,876
+107% +$4.64K
ZVSA
379
DELISTED
ZyVersa Therapeutics
ZVSA
$12.3K ﹤0.01%
+143
New +$37.5K
AFTR.WS
380
DELISTED
AfterNext HealthTech Acquisition Corp Warrants
AFTR.WS
$12.1K ﹤0.01%
139,389
-1,421
-1% -$278
MNTSW icon
381
Momentus Inc Warrant
MNTSW
$15
$12.1K ﹤0.01%
+612,475
New +$20.4K
TWCBW
382
DELISTED
Bilander Acquisition Corp. Warrant
TWCBW
$12K ﹤0.01%
147,050
+62,300
+74% +$5.79K
PLTNW
383
DELISTED
Plutonian Acquisition Corp. Warrant
PLTNW
$11.9K ﹤0.01%
99,900
-330,633
-77% -$23.3K
WGSWW
384
DELISTED
GeneDx Holdings Warrant
WGSWW
$11.7K ﹤0.01%
1,135,974
– –
PIAI.WS
385
DELISTED
Prime Impact Acquisition I Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
PIAI.WS
$11.6K ﹤0.01%
283,364
-31,500
-10% -$1.4K
FEXDR
386
DELISTED
Fintech Ecosystem Development Corp. Right
FEXDR
$11.4K ﹤0.01%
96,200
-4,100
-4% -$508
CVIIW
387
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
$10.5K ﹤0.01%
75,190
-324,750
-81% -$39.5K
PIIIW icon
388
P3 Health Partners Inc Warrant
PIIIW
$207K
$10.4K ﹤0.01%
43,300
– –
GAQ.WS
389
DELISTED
Generation Asia I Acquisition Limited Redeemable Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
GAQ.WS
$10.2K ﹤0.01%
256,617
-235,885
-48% -$21.5K
COOLW
390
DELISTED
Corner Growth Acquisition Corp. Warrant
COOLW
$10.1K ﹤0.01%
79,761
-25,387
-24% -$1.59K
HHLA.WS
391
DELISTED
HH&L Acquisition Co. Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50
HHLA.WS
$10.1K ﹤0.01%
504,440
+500
+0.1% +$24
DMAQR
392
DELISTED
Deep Medicine Acquisition Corp. Rights
DMAQR
$9.98K ﹤0.01%
62,360
-1,903,470
-97% -$311K
DUETW
393
DELISTED
DUET Acquisition Corp. Warrant
DUETW
$9.91K ﹤0.01%
360,301
-47,100
-12% -$1.21K
FLFVR
394
DELISTED
Feutune Light Acquisition Corporation Right
FLFVR
$9.84K ﹤0.01%
98,400
-600
-0.6% -$73
PHYT.WS
395
DELISTED
Pyrophyte Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
PHYT.WS
$9.68K ﹤0.01%
98,000
+50,000
+104% +$4.66K
TGVCW
396
DELISTED
TG Venture Acquisition Corp. Warrants
TGVCW
$9.63K ﹤0.01%
428,717
+78,204
+22% +$3.02K
LSBPW
397
DELISTED
LakeShore Biopharma Warrants
LSBPW
$9.4K ﹤0.01%
+199,999
New +$17K
HMACW
398
DELISTED
Hainan Manaslu Acquisition Corp. Warrant
HMACW
$9.31K ﹤0.01%
252,200
+2,747
+1% +$106
TRCA.WS
399
DELISTED
Twin Ridge Capital Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
TRCA.WS
$9.24K ﹤0.01%
168,882
+500
+0.3% +$32
EVE.WS
400
DELISTED
EVe Mobility Acquisition Corp Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
EVE.WS
$9.1K ﹤0.01%
233,935
-46,765
-17% -$2.39K
14 15
16
17 18

Similar funds

CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
PWLP
Prio Wealth Limited Partnership Boston, Massachusetts $3.41B AUM 44.09% 1-Year Est. Return
FPCG
Fort Pitt Capital Group Pittsburgh, Pennsylvania $3.55B AUM 34.86% 1-Year Est. Return
SI
Scout Investments Kansas City, Missouri $3.8B AUM 45.91% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return

Cowen and Company's Q2 2023 Portfolio in Review

As of Q2 2023, Cowen and Company held 747 positions worth $1.21B, up 42% from $851M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Cowen and Company deployed $316M of net new capital in Q2 2023, opening 182 new positions and adding to 169 existing holdings. Its largest new stake was NVIDIA: 1,927,500 shares worth $81.5M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 38% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $13.9M trimmed.

  • Cowen and Company's largest Q2 2023 buy was NVIDIA: 1,927,500 shares worth $81.5M.
  • Cowen and Company added most to Ares Acquisition Corporation in Q2 2023, an estimated $15.9M increase.
  • Cowen and Company's biggest Q2 2023 reduction was Avadel Pharmaceuticals, cutting an estimated $13.9M.
  • Cowen and Company fully exited Sylvamo in Q2 2023, selling an estimated $99.5M.
  • Cowen and Company's ten largest holdings make up 40% of its $1.21B portfolio in Q2 2023.
  • Cowen and Company opened 182 new positions and closed 163 in Q2 2023.
  • Cowen and Company's portfolio value rose 42% quarter-over-quarter to $1.21B.

Based on Cowen and Company's 13F filing for Q2 2023, filed 7 Aug 2023.